Two isoforms of this protein, mSin1.1 and mSin1.2, are predominantly present in the TORC2 complex (33). embryonic fibroblasts expression of a kinase-dead mutant of mTOR, which FMK inhibits both TORC1 and TORC2, decreases the expression of PTEN via transcriptional mechanism. Furthermore, kinase-dead mTOR increased and decreased phosphorylation of Akt at catalytic loop site Thr-308 and hydrophobic motif site Ser-473, respectively. Moreover, inhibition of deregulated TORC1 in TSC2-null mouse embryonic fibroblasts or in 293 cells by down-regulation of raptor decreased the levels of the transcription factor Hif1 and blocked PTEN expression, resulting in enhanced phosphorylation of Akt at Thr-308 and Ser-473. Finally, knockdown of rictor or mSin1 attenuated the expression of Hif1, which decreased transcription of PTEN. These results unravel a previously unrecognized cell-autonomous function of TORC1 and TORC2 in the up-regulation of PTEN, which prevents phosphorylation of Akt and may shield against the development of malignancy in TSC patients. == Introduction == Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)5represents the most frequently deleted phosphatase and second most frequently deleted tumor suppressor gene in cancer (1). In fact, 5070% of sporadic tumors including prostate tumors, endometrial tumors, and glioblastomas as well as 3050% of lung, breast, and colon cancers show loss of one allele of PTEN (2). Complete loss of PTEN in endometrial tumors, glioblastomas, and BRCA1-deficient breast cancer is usually associated with advanced metastasis (2). Furthermore, germ line mutation of PTEN is usually associated with autosomal dominant developmental disorders, neurological deficiencies, and hamartoma syndromes including Cowden disease, Bannayan-Riley-Ruvalcaba syndrome, and Lhermitte-Duclos disease, which show a FMK high frequency of cancer predisposition (3,4). Growth factor-stimulated class I phosphatidylinositol (PI) 3-kinase family member or its mutated constitutively active catalytic subunit produces phosphatidylinositol 3,4,5-trisphosphate (PIP3), which regulates a myriad of cellular functions such as cell migration, polarity, proliferation, and survival (5,6). PIP3produced in the plasma membrane recruits proteins made up of pleckstrin homology domains such as Akt and PDK-1. Akt activation occurs via phosphorylation by PDK-1 and mTORC2 at two sites, Thr-308 and Ser-473, respectively (7). Structurally, PTEN shares identity with other protein phosphatases in its catalytic domain name (8). Although PTEN has been infrequently reported to dephosphorylate protein substrates, its phosphatase activity toward PIP3represents an important mechanism for its physiological tumor suppressor function (913). Thus, PTEN acts as a negative regulator of PI 3-kinase signal transduction, significantly attenuating the biological activity of Akt. In PTEN-negative cancer cells, Akt is usually constitutively activated and regulates cell growth, proliferation, angiogenesis, and metabolism via phosphorylation of a number of substrates including tuberous sclerosis complex 2 (TSC2) and PRAS40, inactivation of both of which increases rapamycin-sensitive mTORC1 activity (7,14). Mutation in either TSC1 or TSC2 gene contributes to the development of TSC, which manifests as disorders involving pulmonary lymphangiomyomatosis, facial angiosarcomas, and renal angiomyolipomas (15). In addition, TSC patients often display neurological disorders including mental retardation, epilepsy, and autism (16). Clinically, mutations in TSC2 locus contribute more significantly to the manifestation of TSC compared with TSC1 mutation (17). Functionally, TSC1 and TSC2 exist as a heterodimer of which TSC2 contains a GTPase-activating protein domain name. The TSC1TSC2 complex exerts its GTPase-activating protein activity on the small GTPase Ras homolog enriched in brain (Rheb) and blocks mTOR activity (18,19). Genetic FMK studies inDrosophilaand in mammalian cells place TSC2 as a signal integration hub in the PI 3-kinase/Akt/mTOR pathway (19,20). Activated Akt and other mitogenic kinases phosphorylate TSC2 at FMK distinct sites, leading to its dissociation from TSC1 and inactivation (2124). Thus, inactivated TSC2 maintains elevated levels of GTP-bound Rheb, which Rabbit polyclonal to beta defensin131 activates TORC1 to promote tumorigenesis. Enhanced TORC1 activity is usually manifested in pathologic specimens of TSC hamartomas (25,26). Similarly, in PTEN-deficient tumors, increased Akt activity phosphorylates TSC2, resulting in its inactivation, leading to activation of mTOR (7,27). TOR exists in two evolutionary conserved complexes, TORC1 and TORC2; the former is usually more sensitive to rapamycin (28,29). TORC1 and TORC2 contain two distinct proteins, rapamycin-sensitive adaptor protein of mTOR (raptor) and rapamycin-insensitive companion of mTOR (rictor), respectively (28,30,31). Both these complexes bind mLST8/GL and deptor, whereas TORC1 contains PRAS40, and TORC2 contains protor and mSin1 (28,32,33). TORC1 directly phosphorylates the eukaryotic initiation factor 4E-binding proteins (4EBPs) and the ribosomal protein S6 kinase and increases ribosomal biogenesis to elicit cell.